· Op-Ed/Commentary
COVID-19DisabilityDrug AccessHealthcare Massive Public Investment Made COVID-19 Vaccines PossibleShawn FremstadTori Coan / March 09, 2023
· Op-Ed/Commentary
COVID-19InequalityIntellectual Property Moderna’s $130 Vaccine and the Path to Cheap Drugs/ February 14, 2023
· Op-Ed/Commentary
COVID-19DisabilitySpotlightUnited States CEPR Spotlight: DisabilityDawn Niederhauser / December 14, 2022
· Op-Ed/Commentary
COVID-19Economic Crisis and RecoveryInflationUnited StatesWagesWorkers The November Jobs Report Was Not as Strong as AdvertisedDean Baker / December 04, 2022
· Op-Ed/Commentary
COVID-19CryptoIntellectual PropertyUnited States The Pandemic Treaty, Crypto, and InequalityDean Baker / November 18, 2022
· Op-Ed/Commentary
COVID-19Economic Crisis and RecoveryIntellectual Property Washington Post Misleads Readers: China’s COVID-19 Problem Is Not Its Refusal to Use Pharma’s VaccinesDean Baker / November 06, 2022
· Op-Ed/Commentary
COVID-19DisabilityHousehold Pulse SurveyJobsLong COVIDPost-COVIDUnited States The Long Reach of Long COVID: At Least 4.4 Million Adults are Currently Disabled by Long COVIDHayley BrownJulia TacheShawn Fremstad / October 12, 2022
· report
Affordable Care ActCOVID-19Health and Social ProgramsInequalityLong COVIDUnited StatesWorkers Understanding and Addressing Long COVIDShawn FremstadJulia GodfreyHayley BrownAlan Barber / September 29, 2022
· Op-Ed/Commentary
AfghanistanCOVID-19IMFSanctionsSpecial Drawing RightsUS Foreign PolicyWorld Righting the Record: Claims that SDRs “Help US Enemies” Are BaselessMichael Galant / April 14, 2022
· Op-Ed/Commentary
COVID-19Economic Crisis and RecoveryInequality Paul Krugman, China, mRNA Vaccines, and Right-Wing PopulismDean Baker / April 10, 2022